¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21
±³À°ÀÏÀÚ : 2024-06-21
±³À°Àå¼Ò : ¼­¿ï·Ôµ¥È£ÅÚ

±³À°ÁÖÁ¦ : Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2

ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486  

À̸ÞÀÏ : cancer2@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈ­ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ

Âü¼®¿¹»óÀÎ : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 17 ½Ã°£ 55ºÐ

¼¼ºÎ¼ö°­·á : 250,000¿ø  

ºñ°í "1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 12¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 7¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 18¸¸¿ø, 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 18¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 7¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 25¸¸¿ø"


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:00~09:25 Preclinical study of biparatopic ADC targeting MET to overcome acquired resistance to EGFR TKI in EGFR-mutant NSCLC ÀÓ¼±¹Î(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:25~09:50 Next-generation antibody ±èÈ£¹Î(KAIST)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:50~10:15 Engineering next generation T cell therapy for cancer ±èÂùÇõ(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 10:15~10:40 The next generation CAR-T therapies landscape ¼­Çü¼®(¼­¿ï´ë ¾à´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:00~09:25 A system development methodology using protein 3D structure prediction in the field of biomedicine È«µ¿¿Ï(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:25~09:50 Machine leaning on cancer genome and immune data can predict chemotherapy response of upper GI cancers Hidewaki Nakagawa(RIKEN Center for Integrative Medical Sciences)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:50~10:15 AI using multiple clinical & imaging data for cancer research Á¤±Ôȯ(»ï¼ºÀ¶ÇÕÀÇ°úÇпø)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 10:15~10:40 AI development and real-world validation through medical imaging standardization À±¼øÈ£(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:00~09:25 Evolution of the WHO classifications of CNS tumors in the molecular era ±è¼¼ÈÆ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:25~09:50 Lymphoma ÀüÀ±°æ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:50~10:15 Breast tumors Puay Hoon Tan(Duke-NUS Medical School)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 10:15~10:40 Tumors of the gastrointestinal tracts ±è°æ¹Ì(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 09:00~09:20 A first-line treatment option for locally advanced unresectable or metastatic biliary track cancer õÀç°æ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 09:20~10:00 A journey to the hope of HR+/HER2- EBC&MBC patient: Abemaciclib new data ÀÌÁöÀº(°¡Å縯ÀÇ´ë)

ÈÞ½Ä 06¿ù 21ÀÏ 10:40~11:00 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 11:00~11:40 Evolution of cancer treatment and development of Korean Cancer Association ¹æ¿µÁÖ(¼­¿ïÀÇ´ë/¹æ¾Ø¿Á)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 11:40~12:20 How whole genome sequencing can advance precision medicine Emile Voest(Netherlands Cancer Institute)

ÈÞ½Ä 06¿ù 21ÀÏ 12:20~12:30 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 12:30~13:10 Unlocking the door: A paradigm shift in early-stage NSCLC treatment with pembrolizumab À̼¼ÈÆ(¼º±Õ°üÀÇ´ë)

ÈÞ½Ä 06¿ù 21ÀÏ 13:10~14:30 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 14:30~14:55 Whole-genome sequencing reveals the homologous recombination deficiency in human cancer ÁÖ¿µ¼®(KAIST)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 14:55~15:20 Metabolic triggers for cancer genome evolution Ashok Venkitaraman(National University of Singapore)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 15:20~15:45 In vivo CRISPR therapy targeting cancer-specific genetic alterations ±ÇÅÂÁØ(UNIST)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 15:45~16:10 Targeting DNA damage repair deficiency in gynaecological cancers David SP Tan(National University Cancer Institute)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 14:30~14:55 Role of vascular functions in cancer treatment ¼Ûâ¿ø(University of Minnesota)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 14:55~15:20 Vascular regulation of tumor immune exclusion and progression ±è¹Î¾Æ(Columbia University Medical Center)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 15:20~15:45 Hypoxia as a regulator of tumor stroma ÀÌ°æÀº(University of Michigan)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 14:30~14:55 Proteogenomic characterization reveals estrogen signaling as a target for never-smoker lung adenocarcinoma patients without EGFR or ALK alterations ±è¼±¿µ(Çѱ¹»ý¸í°øÇבּ¸¿ø)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 14:55~15:20 Emerging therapeutic targets for systemic treatment of advanced gastric cancer ±èÀÎÈ£(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 15:20~15:45 Single cell-based target identification in cancers ¹ÚÁöȯ(GIST)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 15:45~16:10 Dissecting heterogeneity of histologic patterns reveals a novel target of lung adenocarcinoma À̽ſ±(°æºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 14:30~14:55 Pathology insights in MDT: Driving precision diagnostics and treatment in cancer care ÀÌÇý½Â(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 14:55~15:20 The vital importance of the multidisciplinary team win managing lung cancer: A thoracic surgeon¡¯s view ÀÌ⿵(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 15:20~15:45 Navigating the cancer journey: The integral role of medical oncology in MDT strategies ¹Ú¼¼ÈÆ(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 15:45~16:10 Targeting cancer with precision: The integral role of radiation oncology in MDT strategies À̼º¿í(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 14:30~14:45 ±¹°¡ ¾ÏÁø·á°¡À̵å¶óÀÎ »ç¾÷ ÃßÁø ÇöȲ °ûÈ£½Å(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 14:45~15:00 ¾ÏÁø·á°¡À̵å¶óÀÎ °³¹ß ¹æ¹ý·Ð°ú °Ë¼ö»çÇ× ±è¼ö¿µ(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:00~15:15 À§¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ ÇÑÇý¼÷(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:15~15:30 °©»ó¼±¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ ÀÌÀº°æ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:30~15:45 °áÀå¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ °ûÁ¤¸é(°í·ÁÀÇ´ë)

Åä·Ð 06¿ù 21ÀÏ Belle-Vue 15:45~16:10 ÆгÎÅä·Ð ()

ÈÞ½Ä 06¿ù 21ÀÏ 16:10~16:30 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 16:30~16:50 Tumor informed vs. tumor agnostic ctDNA analysis À̽ÂÅÂ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 16:50~17:10 A new era of molecular residual disease: Optimizing perioperative chemotherapy for colorectal cancer Eiji Oki (Graduate School of Medical Sciences, Kyushu University)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 17:10~17:30 ctDNA monitoring in metastatic cancer ÃÖ¿ø¿µ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 16:30~16:50 Mechanisms of oncogenic tyrosine kinase fusion selection in human cancer Á¤ÅÃÁø(Boston Children)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 16:50~17:10 A study on the immunological microenvironment of pancreatic cancer ±è´ö±â(Ãæ³²´ëº´¿ø)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 17:10~17:30 Immunotherapy in pancreatic cancer: DNA damage repair deficiency & what else ¹Ú¿õ±â(Memorial Sloan Kettering Cancer Center)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22
´ÙÀ½±Û ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
347 ºÎ»ê ´ëÇѺñ´¢±â°úÇÐȸ ¼Ò¾Æºñ´¢ÀÇÇÐ ¹× ³²¼ºÀÇÇÐ : 2018-09-06 0 848 2018-08-08
346 ±¤ÁÖ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ Á¦281Â÷ Àü³²Áöȸ Áý´ãȸ : 2018-09-06 0 387 2018-08-08
345 ÀüºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ÀÎÁöÁßÀçÄ¡·áÀÇ ½ÇÁ¦¿Í Àü¸Á : 2018-09-04 0 556 2018-08-08
344 ºÎ»ê ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ 9¿ù Á¤±âÁý´ãȸ : 2018-09-04 0 516 2018-08-08
343 ¼­¿ï Á¦42ȸ ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø ¾È°ú Áý´ãȸ : 2018-09-03 0 883 2018-08-08
342 ¼­¿ï ¼øõÇâ´ëÇм­¿ïº´¿ø Á¦42ȸ º¹ºÎÃÊÀ½ÆÄ ¹× ³»½Ã°æÃÊÀ½ÆÄ Áø´Ü ¿öÅ©¼ó : 2018-09-02 0 951 2018-08-08
341 ºÎ»ê Á¦21ȸ ´ëÇѳ»°úÇÐȸ ºÎ»ê°æ³²Áöȸ ¿¬¼ö°­Á : 2018-09-02 0 870 2018-08-08
340 ¼­¿ï 2018 ¼Ò¾Æ³»ºÐºñÇÐȸ ¿¬¼ö°­Á : 2018-09-02 0 1,198 2018-08-08
339 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part4, 2ÀÏÂ÷) : 2018-09-02 0 615 2018-08-08
338 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Á¦23ȸ ´ç´¢º´ÀÇ ¿À´Ã°ú ³»ÀÏ : 2018-09-02 0 1,421 2018-08-08
337 ¼­¿ï ´ëÇÑû°¢ÇÐȸ 2018 Á¦19Â÷ º¸Ã»±â¿öÅ©¼¥ : 2018-09-02 0 731 2018-08-08
336 ºÎ»ê 2018³â ´ëÇѹ̼¼¼ö¼úÇÐȸ Ãß°è Microsurgery Workshop : 2018-09-02 0 1,063 2018-08-08
335 ´ëÀü ´ëÇÑÀÓ»ó½Å°æ»ý¸®ÇÐȸ Á¦4ȸ ã¾Æ°¡´Â ¿öÅ©¼ó : 2018-09-02 0 1,031 2018-08-08
334 ´ë±¸ ´ë±¸±¤¿ª½ÃÀÇ»çȸ 2018 Á¾ÇÕÇмú´ëȸ : 2018-09-02 0 756 2018-08-08
333 ¼­¿ï 2018³â ´ëÇÑ¿Ü°úÀÇ»çȸ Ã߰迬¼ö°­Á : 2018-09-02 1 3,030 2018-08-08
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷